Tracking 6 vendors · 83 listings · checked Aug 02Current partner codePEPTIDESDE

InvestigationalWeight lossSubcutaneousEvidence 4/5

Retatrutide

Also known as: LY3437943

Activates GLP-1, GIP and glucagon receptors simultaneously to suppress appetite and raise energy expenditure.

Read full research guide View clinical trials Recheck source availability

This page is a structured profile. Narrative evidence, dosing context and FAQs live on the research guide — not duplicated here as a second full article.

Illustrative profileSubcutaneous

Database profileInvestigational

RetatrutideWeight loss

Drug class: Triple agonist (GLP-1 / GIP / glucagon)
Primary targets: GLP-1R, GIPR, GCGR
Dose reference: 1–12 mg once weekly (trial)
Half-life: ~6 days
Developer / origin: Eli Lilly
Reference year: 2023
Evidence score: 4/5 - Phase 2 human evidence

Evidence 4/5

Phase 2 human evidence

Retatrutide has randomized phase 2 human data in obesity and type 2 diabetes, but it remains investigational and is not an approved drug.

Investigational compound with human randomized or phase 2/3 evidence.

Evidence basis

Human phase 2 obesity trial
Human type 2 diabetes phase 2 trial
No approved indication yet

Key references

How to read this entry

Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.

Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.

Retatrutide guides

Read the matching guide or adjacent research pages for more context.

Retatrutide: The Triple Agonist Posting the Biggest Numbers YetRetatrutide is an investigational triple agonist drawing major attention for weight loss. The trial numbers are striking, and it is still not an approved medicine.Is Retatrutide FDA Approved? Status, Timeline and Access RisksRetatrutide is not FDA approved as of June 12, 2026. The evidence is promising, but the practical answer depends on phase 3 completion, FDA review and regulated labeling.How Does Retatrutide Work? The Triple-Agonist Mechanism ExplainedRetatrutide hits three receptors at once. GLP-1 and GIP cut calorie intake; glucagon is thought to raise energy expenditure. Here's what the science actually shows.Retatrutide Results: How Much Weight Loss Do Studies Show?Retatrutide's trial numbers are striking: about 24% average weight loss at 48 weeks in Phase 2, with Phase 3 topline data going higher. Here's what's verified, and what isn't.

Retatrutide calculator shortcuts

Open peptide calculators with editable Retatrutide example values already filled in.

Retatrutide reconstitution calculatorPrefills a 10 mg vial, 2 mL BAC water and editable dose fields.Open prefilled tool Retatrutide accumulation calculatorPrefills 144 hour half-life and 168 hour interval examples.Open prefilled tool Retatrutide unit converterPrefills 1 mg with a 10 mg vial example.Open prefilled tool

Peptide calculators

Use calculators for concentration, unit conversion and repeated-dose accumulation math.

Peptide reconstitution calculatorCalculate concentration, draw volume and syringe units from vial strength and BAC water.Open tool Peptide accumulation calculatorModel repeated dosing schedules with half-life, interval, peak and trough estimates.Open tool Peptide unit converterConvert mg, mcg, optional IU and syringe units from one reconstituted vial setup.Open tool Peptide chemistry calculatorAnalyze sequence length, molecular weight, composition, charge, hydropathy and notation.Open tool

Compare with related peptides

Stay inside the same research category and compare mechanism, status and evidence quality.

Tirzepatide

LY3298176, Mounjaro, Zepbound

5/5

Weight lossApproved

Activates GLP-1 and GIP receptors to improve glycemic control and reduce appetite + body weight.

Semaglutide

Ozempic, Wegovy, Rybelsus

5/5

Weight lossApproved

Mimics the incretin GLP-1, slowing gastric emptying and reducing appetite while improving insulin secretion.

Liraglutide

Victoza, Saxenda

5/5

Weight lossApproved

Daily GLP-1 analog. Reduces appetite and improves glycemic control via the same incretin pathway as semaglutide.

Cagrilintide

AM833

4/5

Weight lossInvestigational

Long-acting amylin analog that slows gastric emptying and reinforces satiety; studied in combination with semaglutide (CagriSema).

Category hub

Open the category page for the full comparison table and FAQ.

Weight Loss Peptides

Compare weight loss peptides including GLP-1, GIP, amylin and triple-agonist compounds by approval status, mechanism, half-life and evidence score.

Read this first

PeptideStat is educational, not medical advice. Many compounds we cover are investigational or research-only and are not approved for human use. Partner links may earn us a commission without changing your price or our editorial conclusions.

Full disclosure →